Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
June 20th, 2025
1.4K views
Here, we present a protocol to utilize micro-computed tomography (micro-CT) to quantify ventilated regions in a unilateral bleomycin-induced pulmonary fibrosis model via intratracheal instillation on the lesional side.
Overview
This study presents a micro-computed tomography (micro-CT) protocol to quantify ventilated regions in a unilateral bleomycin-induced pulmonary fibrosis model. The approach aims to enhance the assessment of pulmonary fibrosis interventions.
Key Study Components
Area of Science
- Pulmonary fibrosis
- Micro-computed tomography
- Preclinical intervention assessment
Background
- Research focuses on organ fibrosis and developing diagnostic approaches.
- Unilateral bleomycin installation induces targeted lung injury in mice.
- Micro CT enables precise volumetric assessment of lung regions.
- AI-assisted algorithms are being developed for lesion segmentation.
Purpose of Study
- To quantify ventilated lung regions in a fibrosis model.
- To improve the accuracy of intervention evaluations.
- To develop early diagnostic and therapeutic strategies for pulmonary fibrosis.
Methods Used
- Micro-computed tomography for lung volumetric analysis.
- Unilateral bleomycin instillation in a mouse model.
- AI-assisted algorithms for automatic segmentation of fibrotic lesions.
- Comparative analysis of pre-treatment conditions.
Main Results
- Successful quantification of ventilated regions using micro-CT.
- Demonstrated precision in assessing pulmonary fibrosis.
- Potential for transforming preclinical intervention assessments.
- Enhanced accuracy in lesion segmentation through AI algorithms.
Conclusions
- The micro-CT approach provides a reliable method for evaluating pulmonary fibrosis.
- AI-assisted techniques improve the accuracy of quantitative assessments.
- This study lays the groundwork for future therapeutic interventions.
Frequently Asked Questions
What is the significance of using micro-CT in this study?
Micro-CT allows for precise quantification of ventilated lung regions, enhancing the assessment of pulmonary fibrosis.
How does unilateral bleomycin installation affect the study?
It induces targeted lung injury, providing a consistent model for evaluating fibrosis interventions.
What role do AI algorithms play in this research?
AI algorithms assist in automatic segmentation of fibrotic lesions, improving assessment accuracy.
What are the potential applications of this research?
The findings could lead to improved diagnostic and therapeutic strategies for pulmonary fibrosis.
What future directions does this study suggest?
Future research may focus on refining AI techniques and exploring new therapeutic interventions.
Executive Industry Relevance
Quantitative unilateral lung volume analysis using micro-CT enables precise assessment of pulmonary fibrosis progression and therapeutic response in preclinical models. This approach addresses the need for reproducible, sensitive, and translationally relevant endpoints in early-stage respiratory drug discovery. Enhanced volumetric and regional quantification supports confident decision-making at key inflection points in fibrosis portfolio advancement.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rigorous interrogation of fibrotic pathway hypotheses in vivo.
- Supports functional target validation by quantifying lesion-specific lung volume changes.
- Facilitates mechanistic de-risking through precise regional injury modeling.
- Improves predictive confidence for candidate selection in fibrosis programs.
Screening & Assay Development
- Provides standardized, quantitative readouts for evaluating anti-fibrotic interventions.
- Enables reproducible assessment of ventilated lung regions across cohorts.
- Supports assay scalability and platform reuse for longitudinal studies.
- Delivers reliable volumetric endpoints for compound screening workflows.
Translational & Preclinical Research
- Aligns preclinical endpoints with clinically relevant imaging modalities.
- Enables continuity from discovery through preclinical validation of therapeutic efficacy.
- Supports risk-adjusted advancement decisions based on quantitative disease progression metrics.
- Facilitates biomarker alignment through imaging-based fibrosis assessment.
Pipeline & Workflow Integration
This micro-CT-based volumetric analysis integrates into the discovery-to-preclinical continuum for pulmonary fibrosis, bridging early mechanistic studies and translational efficacy evaluation.
- Discovery Biology: Supports hypothesis testing and biological de-risking by quantifying regional fibrotic injury.
- Screening: Provides reproducible, quantitative outputs for intervention assessment and cohort comparison.
- Analytics: Delivers volumetric and aeration metrics to inform statistical analysis and decision thresholds.
- Translational Research: Aligns preclinical imaging endpoints with clinical diagnostic standards.
- Enterprise Reuse: Establishes a reusable imaging and analysis workflow for fibrosis and related lung disease models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in fibrosis models.
- Operational Value: Standardizes volumetric analysis and enhances reproducibility across studies.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio progression.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of respiratory assets.
Implementation Considerations
- Requires expertise in micro-CT imaging and 3D image analysis software.
- Demands access to high-resolution micro-CT instrumentation and computational infrastructure.
- Necessitates cross-team standardization of imaging protocols and analysis parameters.
- Adaptation may be needed for different animal models or fibrosis etiologies.
- Potential limitations include imaging throughput and segmentation accuracy, especially in severe disease states.
Biopharma FAQs
Why does null hypothesis testing matter for micro-CT lung volume analysis?
Null hypothesis testing ensures that observed differences in lung volume or aeration between treated and control groups are statistically significant, supporting robust target validation in fibrosis models.
How does independent variable isolation fit in unilateral bleomycin instillation?
Isolating the lesional side via unilateral instillation allows direct comparison within the same animal, reducing confounding variables and increasing confidence in intervention effects.
What do quantitative dependent variable measurements enable in fibrosis assessment?
Quantitative lung volume and aeration metrics enable sensitive detection of disease progression and therapeutic response, facilitating data-driven advancement decisions.
Why are replication requirements critical for micro-CT volumetric studies?
Replication across cohorts and studies ensures reproducibility and cross-functional confidence in volumetric endpoints, supporting collaborative R&D workflows.
What statistical analysis capabilities are required before implementing micro-CT quantification?
Robust statistical tools are needed to analyze volumetric data, compare groups, and validate significance thresholds, ensuring reliable interpretation for pipeline decisions.
